Andrew Bristol

Health Technology

Consumer Services

Commercial Services

Profile

Dr. Andrew Bristol is Vice President-Research & Development at Synthetic Biologics, Inc. Dr. Bristol was previously employed as Senior Vice President-Research & Development by Neogenix Oncology, Inc., Deputy Director-Immunology by Genetic Therapy, Inc., and a Research Associate by Genetics Institute LLC.
He received his undergraduate degree from the University of California, Berkeley and a doctorate degree from Tufts University.

Former positions of Andrew Bristol

Companies	Position	End
THERIVA BIOLOGICS, INC.	Chief Tech/Sci/R&D Officer	-
Genetic Therapy, Inc. Genetic Therapy, Inc. Miscellaneous Commercial ServicesCommercial Services Genetic Therapy, Inc. develops human gene therapy products for the treatment of genetic and acquired diseases. The company also conducts research on human gene development. Genetic Therapy was founded by M. James Barrett in May 1986 and is headquartered in Gaithersburg, MD.	Corporate Officer/Principal	-
Genetics Institute LLC Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA.	Corporate Officer/Principal	-
Neogenix Oncology, Inc. Neogenix Oncology, Inc. Medical SpecialtiesHealth Technology Founded in December 2003, Neogenix Oncology is a clinical stage biotechnology company focused on developing therapeutic and diagnostic products for the early detection and treatment of cancer. The company's antibody drug candidates and diagnostics are designed to detect and target the tumor without destroying healthy cells. Neogenix Oncology is uniquely positioned to create innovative therapeutics through the use of proprietary cancer vaccines, several of which have demonstrated success in human trials. By marrying this platform with today's breakthrough technologies, the company is developing antibody therapeutics that could change the way it detects and treats cancer.	Chief Tech/Sci/R&D Officer	-

See the detail of Andrew Bristol's experience

Training of Andrew Bristol

Tufts University	Doctorate Degree
University of California, Berkeley	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies